Mesoblast Maintains Momentum With FDA on Accelerated Approval Pathway for Revascor® in Ischemic Heart Failure and Label Extension for Ryoncil® in Adults With GvHD

Stock Information for FFW Corp.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About FFW Corp.

Mesabi Trust Press Release
Mesoblast and FDA Align on Key Items for Revascor® Biologic License Application in Ischemic Heart Failure
FDA Provides Seven Years of Orphan-Drug Exclusive Approval for Ryoncil®
Mesabi Trust Press Release
Appendix 4c Quarterly Activity Report for Quarter Ended March 31, 2025
Mesoblast Appoints Corporate Finance Leader Lyn Cobley To Board
Mesoblast Extends Payer Coverage For Ryoncil® to Over 100 Million US Lives
Mesabi Trust Press Release

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.